

Press Release

For Immediate Distribution

Report from Extraordinary General Meeting in Intervacc

Stockholm, November 23, 2023 - Intervacc AB (publ) has at the request of a group of shareholders, which together control not less than one-tenth of all shares in the company, on 23 November 2023 held an Extraordinary General Meeting ("EGM"), at which the following resolutions were made.

Election of new Board of Directors etc.

The EGM resolved, in accordance with the shareholder group's proposal, that the Board of Directors shall consist of five board members without deputies. Further, the EGM resolved, with the dismissal of all of the current board members, Björn Sjöstrand, Bengt Guss, Niels Holck, Stefan Ståhl, Boel Sundvall, Ed Torr and Michela de Carli, to, in accordance with the shareholder group's proposal, elect Håkan Björklund, Jan-Ingmar Flock, Lisen Bratt Fredricson, Lennart Johansson and Camilla Ramfelt McCarthy, as new board members for the period until the end of the next Annual General Meeting. Håkan Björklund was elected chairperson of the Board of Directors. The resolutions were supported by approximately 55,5 per cent of the votes cast at the EGM, while approximately 44,5 per cent of the votes cast voted against the proposals.

The EGM resolved, in accordance with the shareholder group's proposal, that the fees to the Board of Directors shall be paid with SEK 280,000 to the chairperson of the Board of Directors and SEK 130,000 to each of the other board members. The Annual General Meeting's resolution on fees to the Board of Directors where SEK 280,000 shall be paid to the chairperson of the Board of Directors and SEK 130,000 shall be paid to each of the other board members still remains, however, to be paid in proportion to the time the respective board member has been active during the term of the office.

For more information please contact:

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: jonas.sohlman@intervacc.se

This information is information that Intervace AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for immediate publication, through the agency of the contact person set out above on November 23, 2023.

About Intervace

Intervace AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervace share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10